https://www.ignistherapeutics.com/2026-03-23T08:19:16.171Z1.0https://www.ignistherapeutics.com/news/%E3%80%8C%E9%A6%96%E5%8F%91%E3%80%8DCNS%20%E6%96%B0%E9%94%90%E7%BF%BC%E6%80%9D%E7%94%9F%E7%89%A9%E5%88%B7%E6%96%B02021%E5%B9%B4%E4%B8%AD%E5%9B%BD%E7%94%9F%E7%89%A9%E5%8C%BB%E8%8D%AF%20A%20%E8%BD%AE%E8%9E%8D%E8%B5%84%E9%A2%9D%E7%BA%AA%E5%BD%95%EF%BC%81%E6%90%BA%E6%89%8B%20SK%20%E7%94%9F%E7%89%A9%E5%8C%BB%E8%8D%AF%E4%B8%BA%E6%82%A3%E8%80%85%E5%B8%A6%E6%9D%A5%E5%88%9B%E6%96%B0%E7%96%97%E6%B3%952026-03-23T08:19:16.171Z1.0https://www.ignistherapeutics.com/news/%E5%88%86%E5%AD%90%E7%BB%86%E8%83%9E%E5%8D%93%E8%B6%8A%E4%B8%AD%E5%BF%83%E3%80%81%E4%B8%8A%E6%B5%B7%E7%A7%91%E6%8A%80%E5%A4%A7%E5%AD%A6%E5%92%8C%E7%BF%BC%E6%80%9D%E7%94%9F%E7%89%A9%E5%8C%BB%E8%8D%AF%E8%BE%BE%E6%88%90%E5%90%88%E4%BD%9C%E5%8D%8F%E8%AE%AE2026-03-23T08:19:16.171Z1.0https://www.ignistherapeutics.com/news/%E7%BF%BC%E6%80%9D%E7%94%9F%E7%89%A9%E8%8E%B7%E5%BE%97%20NeuroSigma%20%E6%8E%88%E6%9D%83%E8%AE%B8%E5%8F%AF%E4%BA%8E%E4%B8%AD%E5%9B%BD%E5%BC%80%E5%8F%91%E4%B8%8E%E5%95%86%E4%B8%9A%E5%8C%96%E6%B3%A8%E6%84%8F%E7%BC%BA%E9%99%B7%E5%A4%9A%E5%8A%A8%E9%9A%9C%E7%A2%8D%E7%9A%84%20Monarch%20eTNS%20%E7%B3%BB%E7%BB%9F2026-03-23T08:19:16.171Z1.0https://www.ignistherapeutics.com/news/%E6%80%BB%E6%8A%95%E8%B5%841.6%E4%BA%BF%E7%BE%8E%E5%85%83%EF%BC%81%E4%BB%8A%E5%A4%A9%EF%BC%8C%E7%BF%BC%E6%80%9D%E7%94%9F%E7%89%A9%E5%8C%BB%E8%8D%AF%E5%BC%80%E5%B7%A52026-03-23T08:19:16.171Z1.0https://www.ignistherapeutics.com/en/news/Innovative%20CNS%20Startup%20Ignis%20Therapeutics%20Sets%20New%20Record%20for%202021%20Biopharma%20Series%20A%20Financing%20in%20China.%20Partners%20with%20SK%20Biopharmaceuticals%20to%20Bring%20Innovative%20Therapies%20to%20Patients.2026-03-23T08:19:16.171Z1.0https://www.ignistherapeutics.com/en/news/Center%20for%20Excellence%20in%20Molecular%20Cell%20Science,%20CAS,%20and%20Ignis%20Therapeutics%20Forge%20Collaboration%20Agreement.2026-03-23T08:19:16.171Z1.0https://www.ignistherapeutics.com/en/news/Ignis%20Therapeutics%20Licenses%20NeuroSigma%20eTNS%20Technology%20for%20ADHD%20in%20a%20Significant%20China%20Licensing%20Transaction.2026-03-23T08:19:16.171Z1.0https://www.ignistherapeutics.com/en/news/$160%20Million%20Total%20Investment!%20Today,%20Ignis%20Therapeutics%20Commences%20Construction.2026-03-23T08:19:16.171Z1.0https://www.ignistherapeutics.com/About2026-03-04T03:29:30.604Z1.0https://www.ignistherapeutics.com/Conditions2026-03-04T03:29:30.604Z1.0https://www.ignistherapeutics.com/Dislaimer2026-03-04T03:29:30.604Z1.0https://www.ignistherapeutics.com/en2026-03-04T03:29:30.604Z1.0https://www.ignistherapeutics.com/Innovation-and-Development2026-03-04T03:29:30.604Z1.0https://www.ignistherapeutics.com/Investment2026-03-04T03:29:30.604Z1.0https://www.ignistherapeutics.com/Join-us2026-03-04T03:29:30.604Z1.0https://www.ignistherapeutics.com/Media2026-03-04T03:29:30.604Z1.0https://www.ignistherapeutics.com/en/About2026-03-04T03:29:30.604Z1.0https://www.ignistherapeutics.com/en/Conditions2026-03-04T03:29:30.604Z1.0https://www.ignistherapeutics.com/en/Dislaimer2026-03-04T03:29:30.604Z1.0https://www.ignistherapeutics.com/en/Innovation-and-Development2026-03-04T03:29:30.604Z1.0https://www.ignistherapeutics.com/en/Investment2026-03-04T03:29:30.604Z1.0https://www.ignistherapeutics.com/en/Join-us2026-03-04T03:29:30.604Z1.0https://www.ignistherapeutics.com/en/Media2026-03-04T03:29:30.604Z1.0